[PDF] Top 20 EVALUACIÓN DE PRUEBAS PSICOLOGICAS POR PUESTOS
Has 10000 "EVALUACIÓN DE PRUEBAS PSICOLOGICAS POR PUESTOS" found on our website. Below are the top 20 most common "EVALUACIÓN DE PRUEBAS PSICOLOGICAS POR PUESTOS".
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
... Programmed cell death 1 (PD-1) is a receptor expressed on the surface of activated T cells; 7 it binds to its ligands programmed cell death ligand-1 (PD-L1) and PD-L2, causing downregulation of the ... See full document
91
Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First Line Therapy for Patients with Advanced Non Squamous Non Small Cell Lung Cancer
... of patients, deep vein thrombosis in 9.7% of patients, cardiac infarction in ...of patients and grade III or IV neutropenia in ...of patients experienced at least grade 3 - 4 adverse events ... See full document
48
<p>Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)</p>
... a phase I trial on all NSCLC subtypes. 17 In an early phase II trial of BVZ for NSCLC patients, 18 among six patients experiencing life-threatening pulmonary hemor- rhages, four had ... See full document
37
<p>Clinical utility of ramucirumab in non-small-cell lung cancer</p>
... single-arm study. 22 Forty patients with histologically con fi rmed stage IIIB or IV NSCLC were enrolled in the ...these patients received ramu- cirumab at the dose of 10 mg/kg via intravenous ... See full document
65
FDG PET in the evaluation of response to nivolumab in recurrent non small cell lung cancer
... In patients with recurrent or advanced NSCLC, who have relapsed after previous platinum-based chemother- apy or EGFR-TKI, docetaxel monotherapy is considered to be the current standard treatment ... See full document
201
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
... of nivolumab in advanced-stage squamous NSCLC (Table ...a Phase II single-arm trial of nivolumab in third-line therapy and beyond, 117 patients were treated with ... See full document
14
A Phase II Study of Erlotinib in Patients with Previously Treated Non Small Cell Lung Cancer
... in patients with pre- viously treated advanced NSCLC in the pivotal trial ...of patients with advanced NSCLC who have failed at least 1 prior chemotherapy regimen ...for patients with ... See full document
174
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design
... addition, patients are carefully selected for eligibility, and a protocol of emergency procedures needs to be established and validated by all those involved in the provision of home administration of ... See full document
5
Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
... oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and epidermal growth factor receptor ...including ... See full document
62
Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature
... Immune checkpoint blockade agents have long been incriminated for opening the autoimmune Pandora’s box, with severity of the reported complications ranging from mild to fatal. We herein report a case primary hypo- ... See full document
40
Could molecular pathology testing in lung cancer be more cost effective?
... of patients. The saving represented by only testing patients eligible for treatment with targeted therapies (the request model) would be easily achievable in most clinical laboratories without any ... See full document
43
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
... were advanced NSCLC patients who had tested positive for EML4–ALK fusion and were not receiving crizotinib (n = 36), with EGFR mutation and negative for ALK (n = 67), or negative for both genomic ... See full document
6
Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis
... important phase II study, Belani and colleagues added cetuximab, a chimeric epidermal growth factor receptor (EGFR) inhibitor, to a carboplatin/docetaxel doublet, and patients were allowed to ... See full document
6
A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
... PubMed, Embase, and Cochrane Library databases were searched up to June 2017 by two independent investigators with the following keywords: “non-small cell lung cancer,” and “Programmed ... See full document
15
Systemic therapy in patients with NSCLC with brain metastasis: the emerging role of immunotherapy
... 31. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Jr., Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. ... See full document
10
<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>
... excluded patients trea- ted with anti-PD1/PD-L1 antibody during clinical trials or under off-label use, and also patients with prior or concurrent treatment with an anti-CTLA-4 ... See full document
6
Novel ALK inhibitors in clinical use and development
... 143 patients had an OR of ...arm phase 2 study evaluating safety and efficacy of crizo- tinib (250 mg oral bid every 3 weeks) in patients with ad- vanced ALK positive NSCLC who progressed ... See full document
5
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
... in patients with lung metastases (M1b disease) than in those with other visceral metastases (M1c dis- ease) ...Another study in 337 melanoma patients treated with pembrolizumab or ... See full document
5
Case Report Parotid gland and cerebellum metastasis of lung cancer: a case report
... all cancer-related mortalities are caused by lung cancer. Lung squamous cell carcinoma (SCC) is a common type of non-small-cell lung cancer ... See full document
59
Developments in the Management of Advanced Non Small Cell Lung Cancer
... in patients with advanced non small cell lung cancer (NSCLC) remains to the day highly ...with small molecule tyrosine kinase inhibitors, the role of crizotinib and ... See full document
134
Related subjects